

Melike Melikoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7302128/publications.pdf>

Version: 2024-02-01

46
papers

1,965
citations

394421

19
h-index

345221

36
g-index

46
all docs

46
docs citations

46
times ranked

1572
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. <i>Journal of Rheumatology</i> , 2005, 32, 98-105.	2.0	220
2	Apremilast for Behçet's Syndrome – A Phase 2, Placebo-Controlled Study. <i>New England Journal of Medicine</i> , 2015, 372, 1510-1518.	27.0	204
3	Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. <i>Rheumatology</i> , 2014, 53, 2018-2022.	1.9	172
4	Major vessel involvement in Behçet's disease: an update. <i>Current Opinion in Rheumatology</i> , 2011, 23, 24-31.	4.3	170
5	Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 35-48.	1.0	151
6	Major vessel involvement in Behçet disease. <i>Current Opinion in Rheumatology</i> , 2005, 17, 1-8.	4.3	130
7	Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 1918-1928.	27.0	125
8	The Unique Features of Vasculitis in Behçet's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 40-46.	6.5	84
9	Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. <i>Journal of Rheumatology</i> , 2002, 29, 2393-6.	2.0	77
10	Atherosclerosis in Behçet's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 1-12.	3.4	76
11	Characterization of the Divergent Wound-Healing Responses Occurring in the Pathergy Reaction and Normal Healthy Volunteers. <i>Journal of Immunology</i> , 2006, 177, 6415-6421.	0.8	67
12	Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 369-373.	3.4	64
13	An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 602-609.	3.4	59
14	Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behçet Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1899.	1.0	53
15	Behçet's disease in the Middle East. <i>Clinics in Dermatology</i> , 1999, 17, 209-223.	1.6	49
16	Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. <i>Rheumatology</i> , 2020, 59, 799-806.	1.9	27
17	Secukinumab induced Behçet's syndrome: a report of two cases. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz041.	0.4	26
18	Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. <i>Arthritis Research and Therapy</i> , 2012, 14, R147.	3.5	24

#	ARTICLE	IF	CITATIONS
19	A survey of phenotype II in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 910-913.	0.9	23
20	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. <i>Rheumatology</i> , 2020, 59, 2264-2271.	1.9	21
21	Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. <i>Rheumatology International</i> , 2016, 36, 1719-1725.	3.0	20
22	Infliximab does not suppress the tuberculin skin test (purified protein derivative). <i>Journal of Rheumatology</i> , 2007, 34, 474-80.	2.0	19
23	The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. <i>Respiratory Medicine</i> , 2011, 105, 1739-1747.	2.9	16
24	Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 92-96.	0.8	13
25	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 80-87.	0.8	13
26	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. <i>Rheumatology International</i> , 2018, 38, 607-622.	3.0	12
27	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. <i>Rheumatology International</i> , 2021, , 1.	3.0	8
28	Calciophylaxis: A Report of Six Cases and Review of Literature. <i>Renal Failure</i> , 2013, 35, 163-169.	2.1	7
29	Post-COVID-19 vaccination inflammatory syndrome: A case report. <i>Modern Rheumatology Case Reports</i> , 2023, 7, 280-282.	0.7	7
30	Emergence of new manifestations during infliximab treatment in Behçet's syndrome. <i>Rheumatology</i> , 2022, 61, 3746-3753.	1.9	5
31	Behçet's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006, 5, 185-206.	0.1	4
32	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , 2021, , 1.	3.0	3
33	Biosimilar infliximab for Behçet's syndrome: a case series. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 111-115.	0.8	3
34	Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. <i>RMD Open</i> , 2022, 8, e002235.	3.8	3
35	Vascular and Cardiac Involvement. , 2020, , 83-103.		2
36	Outcome of invasive procedures for venous thrombosis in Behçet's syndrome: case series and systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 125-131.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. <i>Rheumatology</i> , 2022, 62, 9-18.	1.9	2
38	SAT0223â€¦FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. , 2019, , .		1
39	Vascular Disease in Behçet's Syndrome. , 2010, , 115-133.		1
40	The Mucocutaneous Manifestations and Pathergy Reaction in Behçet's Disease. , 2010, , 53-72.		1
41	Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behçet's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 448-450.	0.9	1
42	240.â€¦FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
43	THU0298â€¦INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHÇET'S SYNDROME. , 2019, , .		0
44	FRI0279â€¦MYCOPHENOLATE MOFETIL IN THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF PATIENTS WITH BEHÇET'S SYNDROME. , 2019, , .		0
45	Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply. <i>Rheumatology</i> , 2020, 59, 914-915.	1.9	0
46	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 80-87.	0.8	0